Clinical Efficacy Of Amlavetas In Mutrashmari.

A Pharmacognostical Study Of Amlavetas (Garcinia pedunculata Roxb.) Fruit And To Evaluate Its Efficacy In Mutrashmari w.s.r. To Urolithiasis. - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/12/060841

Enrollment

Registered

2023-12-27

Start date

Unknown

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N202- Calculus of kidney with calculus of ureter

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: kidney Stone Upto 10mm (as measured on USG) Ueteric stone upto 5mm

Exclusion criteria

Exclusion criteria: Patients not willing for trial and follow up Chronic Renal failure. Gross Hydronephrosis. Cases which require surgical intervention. Gross Hematuria ( >50rbc/HPF). Kidney stone size more than 10 mm Ureteric stone size more than 5 mm Known cases of Malignancy, Tuberculosis. Patients with uncontrolled Hypertension & Diabetes Mellitus.

Design outcomes

Primary

Measure	Time frame
Relief in cardinal sign and symptoms (Reduction in pain, burning micturition, hematuria etc) of Mutrashmari (Urolithiasis) on the basis of USG. Evaluation of the drug i.e. Amlavetas [Garcinia pedunculata (Roxb.)] fruit would be assessed on reduction of clinical symptoms of Mutrashmari (Urolithiasis) and improvement in Subjective/Objective parameters as from baseline and after 90 days of therapy.Timepoint: 3 Months	—

Measure

Time frame

Relief in cardinal sign and symptoms (Reduction in pain, burning micturition, hematuria etc) of Mutrashmari (Urolithiasis) on the basis of USG. Evaluation of the drug i.e. Amlavetas [Garcinia pedunculata (Roxb.)] fruit would be assessed on reduction of clinical symptoms of Mutrashmari (Urolithiasis) and improvement in Subjective/Objective parameters as from baseline and after 90 days of therapy.Timepoint: 3 Months

—

Secondary

Measure	Time frame
At the end of the study, five -point Global Assessment scale for efficacy (Cured, Marked improvement, Moderate improvement, Mild improvement, No improvement) will be used.Timepoint: 3 Months	—

Countries

India

Contacts

Public ContactDr Rajesh Sharma

Ayurveda and Unani tibbia college Karol Bagh New Delhi

rajsakshi.sharma@gmail.com9868092250

Outcome results